Tocilizumab

Name Value
Weight 0.000 N/A
Zinc ID N/A
Smiles N/A
Molecular formula N/A
Mode of inhibition Monoclonal antibody to IL6R; JAK/STAT inhibitor
CAS 375823-41-9

Clinical Trials

Study title Status Conditions Link
Use of Tocilizumab for Rheumatoid Arthritis (RA) in Daily Routine Completed Rheumatoid Arthritis NCT02809833
Tocilizumab in Children With ACP Recruiting Adamantinomatous Craniopharyngioma NCT03970226
A Longitudinal Study of ACTEMRA® (Tocilizumab) as Monotherapy in Highly Active NMOSD Completed Neuromyelitis Optica Spectrum Disorders|Neuromyelitis Optica|Devic's Disease NCT03062579
EMBRACE-SC: Observational Study of Subcutaneous (SC) Tocilizumab Alone or in Combination With Conventional Disease-Modifying Antirheumatic Drugs (cDMARDs) in Rheumatoid Arthritis Completed Rheumatoid Arthritis NCT02648035
A Retrospective Cohort Study on the Risk of Serious Infections in Rheumatoid Arthritis Patients Receiving Tocilizumab Not yet recruiting Infection|Rheumatoid Arthritis NCT04115423
Study of the Safety, Tolerability, and Bioactivity of Tocilizumab On Patients With Non-infectious UVEITIS: The STOP-UVEITIS Study Unknown status Intermediate Uveitis|Posterior Uveitis|Pan-uveitis NCT01717170
Study of Tocilizumab in Patients With Hepatocellular Carcinoma (HCC) Undergoing Transarterial Chemoembolization (TACE) Withdrawn Hepatocellular Carcinoma NCT02997956
Tocilizumab for the Treatment of Refractory Behcet's Uveitis Recruiting Behcet Syndrome|Uveitis NCT03554161
An Observational Study of Tocilizumab (Actemra) in Participants With Moderate to Severe Rheumatoid Arthritis Completed Rheumatoid Arthritis NCT01741688
Itacitinib and Tocilizumab for Steroid Refractory Acute Graft Versus Host Disease Not yet recruiting Steroid Refractory GVHD|Graft Vs Host Disease NCT04070781
Tocilizumab Augmentation in Treatment-Refractory Major Depressive Disorder Recruiting Major Depressive Disorder NCT02660528
Tocilizumab for Cytokine Release Syndrome Prophylaxis in Haploidentical Transplantation Recruiting Cytokine Release Syndrome|Stem Cell Transplant Complications NCT03533101
A Non-Interventional Study of Rheumatoid Arthritis Patients Treated With RoActemra/Actemra (Tocilizumab) in Monotherapy Completed Rheumatoid Arthritis NCT01705730
A Non-interventional Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis Completed Rheumatoid Arthritis NCT01562327
Tocilizumab for Treatment of Steroid Refractory Acute Graft-versus-Host Disease Terminated Acute Graft Versus Host Disease NCT01475162
Tocilizumab Plus a Short Prednisone Taper for GCA Recruiting Giant Cell Arteritis NCT03726749
Therapeutic Drug Monitoring of Tocilizumab in Rheumatoid Arthritis Recruiting Rheumatoid Arthritis|Tocilizumab NCT03781310
An Open-Label Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis Completed Rheumatoid Arthritis NCT01951170
Single Patient Use of Tocilizumab in Systemic Onset Juvenile Idiopathic Arthritis Terminated Arthritis, Juvenile Rheumatoid|Still's Disease, Juvenile Onset NCT00868751
A Time to Cardiovascular Event Analysis Comparing Tocilizumab to Other Biologics in Patients With Rheumatoid Arthritis (RA) Unknown status Rheumatoid Arthritis NCT02797769
A Study to Evaluate Pharmacokinetics and Safety of Tocilizumab (RoActemra/Actemra) in Participants Less Than 2 Years Old With Active Systemic Juvenile Idiopathic Arthritis (sJIA) Completed Juvenile Idiopathic Arthritis NCT01455701
Tocilizumab as Add-On Treatment For Residual Positive, Negative, and Cognitive Symptoms of Schizophrenia Completed Schizophrenia|Schizoaffective Disorder NCT02034474
Pilot Study of Tocilizumab in Patients With Erdheim-Chester Disease Terminated Erdheim-Chester Disease NCT01727206
A Study of the Efficacy and Safety of Tocilizumab in Adults With Rheumatoid Arthritis. Completed Rheumatoid Arthritis NCT01988012
Tocilizumab for SARS-CoV2 Severe Pneumonitis Not yet recruiting SARS Pneumonia NCT04315480
A Study of Subcutaneously Administered Tocilizumab in Participants With Systemic Juvenile Idiopathic Arthritis Completed Juvenile Idiopathic Arthritis NCT01904292
Safety and Efficacy of tocilizuMAb Versus Placebo in Polymyalgia rHeumatica With glucocORticoid dEpendence SEMAPHORE Active, not recruiting Polymyalgia Rheumatica NCT02908217
An Observational Study of RoActemra/Actemra (Tocilizumab) As Monotherapy in Rheumatoid Arthritis Patients in Routine Clinical Practice Completed Rheumatoid Arthritis NCT01474291
Extension Study Evaluating the Safety and Efficacy of Subcutaneous Tocilizumab (RoActemra/Actemra) Administration in Systemic and Polyarticular-Course Juvenile Idiopathic Arthritis Active, not recruiting Juvenile Idiopathic Arthritis NCT02165345
An Extension Study to Evaluate Long-Term Safety of Subcutaneous (SC) Tocilizumab in Participants With Giant Cell Arteritis (GCA) Completed Giant Cell Arteritis NCT03202368
A Long Term Extension Study of WA19926 (NCT01007435) of Tocilizumab (RoActemra/Actemra) in Participants With Early, Moderate to Severe Rheumatoid Arthritis (RA) Completed Rheumatoid Arthritis NCT01668966
Tocilizumab vs Azathioprine in Neuromyelitis Optica Spectrum Disorders Completed Neuromyelitis Optica Spectrum Disorders|Neuromyelitis Optica NCT03350633
A Long-Term Extension Study to WA19926 (NCT01007435) of Tocilizumab in Participants With Early, Moderate to Severe Rheumatoid Arthritis Terminated Rheumatoid Arthritis NCT01665430
Tocilizumab for Relapsing Polychondritis Withdrawn Relapsing Polychondritis NCT01104480
Tocilizumab in COVID-19 Pneumonia (TOCIVID-19) Recruiting COVID-19 Pneumonia NCT04317092
An Open-Label Trial of Tocilizumab in Schizophrenia Completed Schizophrenia NCT01696929
Study of Tocilizumab to Treat Polymyalgia Rheumatica Completed Polymyalgia Rheumatica (PMR) NCT01396317
A Long-Term Extension Study of WA19926 on the Safety of Tocilizumab (RoActemra/Actemra) in Participants With Early Moderate to Severe Rheumatoid Arthritis Completed Rheumatoid Arthritis NCT01655381
Short-Term Application of Tocilizumab Following Myocardial Infarction Completed Myocardial Infarction NCT02419937
Non-Interventional Study of Tocilizumab Subcutaneous (SC) Monotherapy in Participants With Rheumatoid Arthritis (RA) Completed Rheumatoid Arthritis NCT02402686
Phase I, Pharmacokinetic, Safety and Tolerability Study in Healthy Volunteers Completed Pharmacokinetics NCT03522012
Tocilizumab (TCZ) in New-onset Type 1 Diabetes Active, not recruiting Type 1 Diabetes Mellitus|New-onset Type 1 Diabetes Mellitus|T1DM|T1D NCT02293837
Tocilizumab and Hemophagocytic Lymphohistiocytosis (HLH) Recruiting Hemophagocytic Lymphohistiocytosis NCT02007239
Tocilizumab in Patients With Schnitzler's Syndrome Completed Schnitzler's Syndrome NCT03046381
Study of the Response and Cardiorespiratory Endurance in Early RA Patients Treated With Tocilizumab or Methotrexate Completed Rheumatoid Arthritis NCT01245452
A Study in Patients With Moderate to Severe Active Rheumatoid Arthritis Comparing Different Infusion Durations of RoActemra/Actemra (Tocilizumab) Treatment Completed Rheumatoid Arthritis NCT01468077
Effect of Subcutaneous ACTEMRA on Inflamed Atherosclerotic Plaques in Patients With Rheumatoid Arthritis Enrolling by invitation Rheumatoid Arthritis NCT02659150
A Study to Evaluate the Efficacy of Tocilizumab as a Remission-Induction and Glucocorticoid-Sparing Regimen in Subjects With New-Onset Polymyalgia Rheumatica (PMR- SPARE) Recruiting Polymyalgia Rheumatica NCT03263715
TOSCARA Study: A Study of Subcutaneous Tocilizumab (RoActemra/Actemra) in Participants With Active Rheumatoid Arthritis NaĂŻve to RoActemra/Actemra Treatment Completed Rheumatoid Arthritis NCT02031471
Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis Completed Dermatomyositis|Polymyositis NCT02043548
A Study of Decreased Dose Frequency in Participants With Systemic Juvenile Arthritis Who Experience Laboratory Abnormalities During Treatment With RoActemra/Actemra (Tocilizumab) Completed Juvenile Idiopathic Arthritis NCT01734382
A Long-term Safety Extension Study of Tocilizumab in Brazilian Participants With Rheumatoid Arthritis (RA) Who Completed the Studies ML21530 and MA21488 Completed Arthritis, Rheumatoid NCT01715831
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Tocilizumab (TCZ) Administered to Participants With Giant Cell Arteritis (GCA). Active, not recruiting Giant Cell Arteritis NCT03923738
Tocilizumab in Cardiac Transplantation Recruiting Heart Transplant NCT03644667
Tocilizumab for the Treatment of Behcet's Syndrome Terminated Behcet Syndrome NCT01693653
A Phase IV Study to Evaluate the Effect of Subcutaneous (SC) Tocilizumab Administered to Participants With Rheumatoid Arthritis (RA) Assessed Using Disease Activity Score (DAS28) Completed Rheumatoid Arthritis NCT02534311
A Pilot Study in Severe Patients With Takayasu Arteritis. Recruiting Takayasu Arteritis|Tocilizumab|Adalimumab|Treatment NCT04300686
Tocilizumab in the Management of Juvenile Idiopathic Arthritis Associated Uveitis Terminated Juvenile Idiopathic Arthritis Associated Uveitis NCT01603355
Efficacy and Tolerance of Tocilizumab In Takayasu Arteritis Unknown status TAKAYASU ARTERITIS NCT02101333
Filling Bone Erosions: a Longitudinal Multicentric HR-pQCT Study of Subcutaneous Tocilizumab in Rheumatoid Arthritis Recruiting Rheumatoid Arthritis NCT02765074
Tocilizumab vs CRRT in Management of Cytokine Release Syndrome (CRS) in COVID-19 Recruiting Covid-19|SARS|Cytokine Storm|Cytokine Release Syndrome|Tocilizumab NCT04306705
A Study of Subcutaneous (SC) Tocilizumab (RoActemra/Actemra) in Participants With Active Rheumatoid Arthritis (RA) and Inadequate Response to Disease-Modifying Anti-Rheumatic Drugs (DMARDs) Completed Rheumatoid Arthritis NCT02046616
Phase II Study of Tocilizumab for Patients With Glucocorticoid-refractory Acute GVHD After Allogeneic Hematopoetic Stem Cell Transplant (HSCT) Terminated Glucocorticosteroid Refractory Acute GVHD NCT01757197
Use of Tocilizumab Drug Levels to Optimize Treatment in RA Recruiting Rheumatoid Arthritis NCT03895879
A Non-Interventional Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis Completed Rheumatoid Arthritis NCT01670045
TOward the Lowest Effective DOse of Abatacept or Tocilizumab Active, not recruiting Rheumatoid Arthritis NCT01557374
Tocilizumab (RoActemra) and Tranexamic Acid (Cyklokapron) Used as Adjuncts to Chronic Subdural Hematoma Surgery Recruiting Chronic Subdural Hematoma NCT03353259
Single Patient Study to Treat Relapsing Polychondritis With Tocilizumab Completed Relapsing Polychondritis NCT01041248
Trastuzumab and Pertuzumab in Combination With Tocilizumab in Subjects With Metastatic HER2 Positive Breast Cancer Resistant to Trastuzumab Recruiting Breast Cancer NCT03135171
A Study on Safety and Efficacy of Tocilizumab (RoActemra/Actemra) Alone or in Combination With Non-Biologic Antirheumatics in Participants With Rheumatoid Arthritis Completed Rheumatoid Arthritis NCT01987479
A Trial of Tocilizumab in ALS Subjects Completed ALS|Amyotrophic Lateral Sclerosis|Lou Gehrig's Disease|Motor Neuron Disease NCT02469896
A Long-Term Extension Study of WA22762 to Evaluate Safety and Efficacy of Subcutaneous Tocilizumab in Participants With Moderate to Severe Rheumatoid Arthritis (RA). Completed Rheumatoid Arthritis NCT01734993
A Study to Evaluate the Use of Glucocorticoids in Combination With Tocilizumab in Daily Clinical Practice Active, not recruiting Rheumatoid Arthritis NCT03291457
Uncontrolled Study to Evaluate Efficacy of Tocilizumab in Patients With Moderate or Severe Rheumatoid Arthritis Unknown status Arthritis, Rheumatoid NCT02087696
A Safety Study of Tocilizumab to Improve Transplant Rates in Highly Sensitized Patients Awaiting Kidney Transplantation Completed End Stage Renal Disease (ESRD) NCT01594424
A Long-term Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients With Rheumatoid Arthritis Completed Rheumatoid Arthritis NCT00721123
A Study of the Efficacy and Safety of Tocilizumab in Participants With Systemic Sclerosis (SSc) Completed Systemic Sclerosis NCT02453256
Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019 Recruiting COVID-19 NCT04310228
Tocilizumab for Renal Graft Inflammation Completed Late Complication From Kidney Transplant NCT02108600
A Study of Tocilizumab (RoActemra/Actemra) in Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Participants With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biologic DMARD Therapy or the First Anti-TNF Biologic Agent Completed Rheumatoid Arthritis NCT02046603
A Study to Evaluate Efficacy of Tocilizumab Administered as Monotherapy or in Combination With Methotrexate and/or Other Disease Modifying Antirheumatic Drugs (DMARDs) in Rheumatoid Arthritis (RA) Participants Completed Rheumatoid Arthritis NCT01941940
A Study of Tocilizumab in Combination With Disease-Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Moderate to Severe Active Rheumatoid Arthritis With an Inadequate Response to DMARDs Completed Rheumatoid Arthritis NCT00996606
A Study of RoActemra/Actemra (Tocilizumab) in Adult Patients With Rheumatoid Arthritis (SVOBODA Programme) Completed Rheumatoid Arthritis NCT02010216
Evolution of Adipokines and Body Composition in Rheumatoid Arthritis Patients Receiving Tocilizumab Therapy Completed Arthritis, Rheumatoid NCT02843789
Tocilizumab Real-Life Human Factors (RLHFs) Validation Study Completed Rheumatoid Arthritis NCT02682823
A Study of Tocilizumab in Participants With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Non-Biological Disease-modifying Anti-rheumatic Drugs (DMARDs) Completed Rheumatoid Arthritis NCT01617005
Success of Tocilizumab in RA Patients With Remission Induction and Sustained Efficacy After Discontinuation Completed Rheumatoid Arthritis NCT01120366
Musculoskeletal Ultrasound in Predicting Early Dose Titration With Tocilizumab Completed Rheumatoid Arthritis NCT01717859
Ranibizumab for Edema of the mAcula in Diabetes: Protocol 4 With Tocilizumab: The READ-4 Study Withdrawn Diabetic Macular Edema NCT02511067
A Study of Tocilizumab in Combination With an Oral Contraceptive in Patients With Rheumatoid Arthritis Completed Rheumatoid Arthritis NCT01044498
An Efficacy and Safety Study of Tocilizumab (RoActemra/Actemra) in Participants With Giant Cell Arteritis (GCA) Completed Giant Cell Arteritis NCT01791153
Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic Transplant Recruiting Acute Leukemia|Chronic Leukemia|Lymphoma|Myelodysplastic Syndromes NCT03588936
Tocilizumab for KSHV-Associated Multicentric Castleman Disease Active, not recruiting Castleman Disease|Castleman's Disease|Giant Lymph Node Hyperplasia NCT01441063
A Study of RoActemra/Actemra (Tocilizumab) in Patients With Ankylosing Spondylitis Who Have Failed Treatment With NSAIDs Terminated Spondylitis, Ankylosing NCT01209702
A Study of Tocilizumab and Methotrexate Treatment Strategies (Adding Tocilizumab to Methotrexate Versus Switching to Tocilizumab) in Patients With Active Rheumatoid Arthritis With Inadequate Response to Prior Methotrexate Treatment Completed Rheumatoid Arthritis NCT00810199
Tocilizumab in Schizophrenia Recruiting Schizophrenia|Psychotic Disorders NCT02874573
A Study of Subcutaneous Tocilizumab as Monotherapy and/or in Combination With Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Rheumatoid Arthritis Completed Rheumatoid Arthritis NCT01941095
Mechanistic Studies of B- and T-Cell Function in RA Patients Treated With TNF Antagonists, Tocilizumab, or Abatacept Active, not recruiting Rheumatoid Arthritis (RA) NCT02353780
PROACTIVE: Preventing Acute/Chronic GVHD With TocIlizumab Combined With GVHD Prophylaxis Post allogEneic Transplant Recruiting Hematologic Malignancy NCT03699631
Efficacy of Tocilizumab for the Treatment of Acute AION Related to GCA Not yet recruiting Giant Cell Arteritis|Optic Ischaemic Neuropathy NCT04239196
A Study of RoActemra/Actemra (Tocilizumab) Given Subcutaneously in Combination With Traditional DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis Completed Rheumatoid Arthritis NCT01232569
Comparing the Efficacy of Periarticular Bone Structure in Patients Treated With Either Tocilizumab or Tumor Necrosis Factor Blockers Completed Rheumatoid Arthritis NCT02778789
A Study of Tocilizumab in Comparison to Etanercept in Participants With Rheumatoid Arthritis and Cardiovascular Disease Risk Factors Completed Rheumatoid Arthritis NCT01331837
The Comparative Study of Intra-articular Injection of Tocilizumab and Compound Betamethasone Unknown status Rheumatoid Arthritis of Knee NCT03215407
A Study of Tocilizumab in Patients With Active Polyarticular Juvenile Idiopathic Arthritis Completed Juvenile Idiopathic Arthritis NCT00988221
Tocilizumab Dose-tapering and Interruption in Patients With Giant Cell Arteritis Achieving the Clinical Remission. Unknown status Giant Cell Arteritis NCT03244709
TOCILIZUMAB IN FIBROUS DYSPLASIA OF BONE Completed Fibrous Dysplasia of Bone NCT01791842
Tocilizumab for the Treatment of Familial Mediterranean Fever Recruiting Familial Mediterranean Fever NCT03446209
Study of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release Syndrome Active, not recruiting Lymphoblastic Leukemia, Acute, Childhood NCT02906371
Efficacy and Safety of Tocilizumab in Adult's Still Disease Unknown status Adult's Still Disease NCT01002781
Study to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Participants With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Non-Biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) and/or Anti-tumor Necrosis Factor (Anti-TNF) Therapy Completed Rheumatoid Arthritis NCT01362062
A Study of Tocilizumab (RoActemra/Actemra) Versus Adalimumab in Patients With Rheumatoid Arthritis Completed Rheumatoid Arthritis NCT01119859
Tocilizumab for Patients With Giant Cell Arteritis Completed Giant Cell Arteritis NCT01450137
A Study of Tocilizumab (RoActemra) in Tocilizumab-Naive Participants With Rheumatoid Arthritis and Inadequate Response to Non-Biologic Disease-Modifying Antirheumatic Drugs (DMARDs) and/or Biologic Therapy Completed Rheumatoid Arthritis NCT02001987
A Long-Term Extension Study of WA22763 and NA25220 of Subcutaneous RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis Completed Rheumatoid Arthritis NCT01772316
Local, Non-Interventional Study of RoActemra (Tocilizumab) in Poland (ACT-POL): First-Line Treatment in Routine Clinical Practice of Participants With Rheumatoid Arthritis (RA) Completed Rheumatoid Arthritis NCT02234960
Ultrasound as Imaging Biomarker of Early Response to Tocilizumab and Methotrexate in Very Early Rheumatoid Arthritis Unknown status Rheumatoid Arthritis NCT02837146
Tocilizumab for Chronic Graft-versus-Host Disease Treatment Withdrawn Graft Versus Host Disease NCT02174263
A Study of Tocilizumab (RoActemra/Actemra) in Patients With Ankylosing Spondylitis Who Have Had an Inadequate Response to Previous Tumor Necrosis Factor (TNF) Antagonist Therapy Terminated Spondylitis, Ankylosing NCT01209689
Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab in Pancreatic Cancer Patients Recruiting Unresectable Pancreatic Carcinoma NCT02767557
An Extension Study of Tocilizumab (Myeloma Receptor Antibody [MRA]) in Patients Completing Treatment in Tocilizumab Core Studies Completed Rheumatoid Arthritis NCT00720798
Effect of the Interleukin-6 Receptor Antagonist Tocilizumab in Patients With Hand Osteoarthritis Completed Hand Osteoarthritis NCT02477059
Evaluation of Tocilizumab as an add-on Therapy to Corticoids in Giant Cell Arteritis: Proof of Concept Study. Completed Giant Cell Arteritis NCT01910038
A Prospective Observational Study of Tocilizumab (RoActemra/Actemra) in Participants With Rheumatoid Arthritis Completed Rheumatoid Arthritis NCT01462162
A Study to Evaluate Tocilizumab Treatment in a Real-Life Setting Completed Rheumatoid Arthritis NCT01664104
An Extension to Study MA21573, Evaluating Tocilizumab in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biological DMARDs and/or Anti-tumor Necrosis Factor (TNF) Therapy Completed Rheumatoid Arthritis NCT00883753
Feasibility of the Combination of Chemotherapy (Carbo/Caelyx or Carbo/Doxorubicin) With Tocilizumab (mAb IL-6R) and Peg-Intron in Patients With Recurrent Ovarian Cancer Completed Recurrent Ovarian Cancer NCT01637532
A Non-Interventional Study Evaluating Rheumatoid Arthritis Participants Treated With Tocilizumab (RoActemra/Actemra) Completed Rheumatoid Arthritis NCT01671059
A Study of Tocilizumab in Chinese Participants With Systemic Juvenile Idiopathic Arthritis (sJIA) Recruiting Juvenile Idiopathic Arthritis NCT03301883
Tocilizumab Treatment in Graves´ Ophthalmopathy (Graves´ Orbitopathy or Thyroid Eye Disease) Completed Thyroid Associated Ophthalmopathies|Graves´ Ophthalmopathy|Thyroid Eye Disease NCT01297699
A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Participants With Moderate to Severe Active Rheumatoid Arthritis Completed Rheumatoid Arthritis NCT01194414
A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma Recruiting Melanoma NCT03999749
Study to Compare the Efficacy of Tocilizumab With or Without Glucocorticoid Discontinuation in Rheumatoid Arthritis Participants Completed Rheumatoid Arthritis NCT02573012
Effect of the Interleukin-6 Receptor Antagonist Tocilizumab in Non-ST Elevation Myocardial Infarction Completed Non-ST Elevation Myocardial Infarction NCT01491074
Alemtuzumab or Tocilizumab in Combination With Etoposide and Dexamethasone for the Treatment of Adult Patients With Hemophagocytic Lymphohistiocytosis Recruiting Leukemia NCT02385110
Single-dose Study to Describe the Safety of Sarilumab and Tocilizumab in Patients With Rheumatoid Arthritis Completed Rheumatoid Arthritis NCT02404558
A Therapeutic Open Label Study of Tocilizumab in the Treatment of Pulmonary Arterial Hypertension Completed Pulmonary Arterial Hypertension NCT02676947
An Efficacy and Safety Study of Subcutaneous Tocilizumab in Combination With Methotrexate (MTX) and as Monotherapy Versus MTX in Participants With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Current Disease-Modifying Antirheumatic Drug (DMARD) Therapy Recruiting Rheumatoid Arthritis NCT03155347
A Study Evaluating the Safety of Tocilizumab in Addition to Standard of Care Premedication Given Before Obinutuzumab + Chlorambucil in Participants With Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Comorbidities Terminated B-Cell Chronic Lymphocytic Leukemia NCT02336048
Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis Completed Rheumatoid Arthritis NCT01579006
A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis Completed Rheumatoid Arthritis NCT01007435
Efficacy of Tocilizumab in Primary Sjögren's Syndrome. Completed Primary Sjögren's Syndrome (pSS) NCT01782235
A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Juvenile Idiopathic Arthritis Who Completed WA19977 Core Study Completed Juvenile Idiopathic Arthritis NCT01667471
Effect of Monoclonal Anti-IL6 Antibody (Tocilizumab) on the Cardiovascular Risk in Patients With Rheumatoid Arthritis Unknown status Rheumatoid Arthritis NCT01752335
A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate (MTX) in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One Tumor Necrosis Factor (TNF)-Inhibitor Terminated Rheumatoid Arthritis NCT01283971
A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Juvenile Idiopathic Arthritis From France Who Completed WA19977 Core Study Completed Juvenile Idiopathic Arthritis NCT01673919
Efficacy and Safety Study of RoActemra (Tocilizumab) in Participants With Rheumatoid Arthritis Completed Rheumatoid Arthritis NCT02721004
Abatacept vs Tocilizumab for the Treatment of RA in TNF Alpha Inhibitor Inadequate Responders Recruiting Arthritis, Rheumatoid NCT03227419
Immunoregulatory Mechanisms of Treg Cells Induced by Tocilizumab Completed Arthritis,Rheumatoid NCT02963402
A Study With Tocilizumab [RoActemra/Actemra] Monotherapy or in Combination With Methotrexate in Patients With Rheumatoid Arthritis (PICTURE) Completed Rheumatoid Arthritis NCT01063062
A Long-Term Extension Study of WA22762 and NA25220 of Subcutaneous (SC) Tocilizumab (TCZ) in Moderate to Severe Rheumatoid Arthritis (RA) Completed Rheumatoid Arthritis NCT01662063
A Study to Assess Efficacy With Respect to Clinical Improvement in Disease Activity and Safety of Tocilizumab in Patients Wtih Active Rheumatoid Arthritis. Completed Rheumatoid Arthritis NCT00754559
A Study of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis Completed Rheumatoid Arthritis NCT00531817
A Study of the Effect of Tocilizumab on Markers of Atherogenic Risk in Patients With Moderate to Severe Rheumatoid Arthritis Completed Rheumatoid Arthritis NCT00535782
Tocilizumab REMission in Early RA Completed Rheumatoid Arthritis NCT04157010
Tocilizumab Effect iN pOlymyalgia Rheumatica Completed Polymyalgia Rheumatica NCT01713842
A Study of Tocilizumab With or Without Methotrexate in Patients With Rheumatoid Arthritis. Completed Rheumatoid Arthritis NCT01010503
A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Early Moderate to Severe Rheumatoid Arthritis Who Completed Study WA19926 Completed Rheumatoid Arthritis NCT01730456
A Study Of Tocilizumab in Patients With Moderate to Severe Active Rheumatoid Arthritis Who Have an Inadequate Response to or Are Unable to Tolerate Biologic and Non-Biologic Disease-modifying Antirheumatic Drugs (DMARDs) Completed Rheumatoid Arthritis NCT00891020
A Study to Assess the Effect of Tocilizumab + Methotrexate on Prevention of Structural Joint Damage in Patients With Moderate to Severe Active Rheumatoid Arthritis (RA) Completed Rheumatoid Arthritis NCT00106535
A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia Not yet recruiting COVID-19 Pneumonia NCT04320615
Randomized Trial Comparing Efficacy of Adalimumab, Anakinra and Tocilizumab in Non-infectious Refractory Uveitis Unknown status Uveitis|Biotherapy NCT02929251
Extension Study of Tocilizumab Long Term Treatment of Moderate to Severe Rheumatoid Arthritis Patients Completed Rheumatoid Arthritis NCT01347983
An Open-label Study With Tocilizumab in Patients With Rheumatoid Arthritis in a Local Environment Completed Rheumatoid Arthritis NCT01254331
An Extension Study of WA19926 of the Long-Term Safety of RoActemra/Actemra (Tocilizumab) in Patients With Early Moderate to Severe Rheumatoid Arthritis Completed Rheumatoid Arthritis NCT01664598
Giant Cell Arteritis Treatment With Ultra-short Glucocorticoids and Tocilizumab Recruiting Giant Cell Arteritis NCT03745586
An Extension Long-Term Study of RoActemra/Actemra (Tocilizumab) in Patients With Polyarticular Juvenile Idiopathic Arthritis Who Completed The WA19977 Study Completed Juvenile Idiopathic Arthritis NCT01727986
Study of Tocilizumab in Combination With Methotrexate for Treatment of Moderate to Severe Rheumatoid Arthritis Patients Completed Rheumatoid Arthritis (RA) NCT01258712
A Study of Administration of RoActemra/Actemra (Tocilizumab) by Auto-injector Vs. Pre-filled Syringe in Healthy Volunteers Completed Healthy Volunteer NCT01418989
Effect of Tocilizumab to the Cellular Immune Response to Influenza Vaccine Unknown status Rheumatoid Arthritis|Cellular Immune Response NCT01980836
Study to Describe Real World Drug Retention Rate of the Tocilizumab at One Year Completed Rheumatoid Arthritis NCT02608112
To Evaluate 1 Year Extension Study of the Efficacy and Safety of Tocilizumab in Patients With Moderate to Severe Rheumatoid Arthritis Completed Rheumatoid Arthritis NCT01256736
A Study of RoActemra/Actemra (Tocilizumab) Versus Placebo in Patients With Systemic Sclerosis Completed Sclerosis, Systemic NCT01532869
A Study of the Effects of RoActemra/Actemra on Vaccination in Patients With Rheumatoid Arthritis on Background Methotrexate (VISARA) Completed Rheumatoid Arthritis NCT01163747
A Study of Subcutaneously (SC) Administered Tocilizumab (TCZ) in Participants With Polyarticular-Course Juvenile Idiopathic Arthritis (pJIA) Completed Juvenile Idiopathic Arthritis NCT01904279
Phase II Open-Label Trial of Tacrolimus/Methotrexate and Tocilizumab for the Prevention of Acute Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Completed Hematopoietic Stem Cell Transplantation NCT02206035
An Observational Study on RoActemra/Actemra (Tocilizumab) in Clinical Practice in Patients With Rheumatoid Arthritis (TRUST) Completed Rheumatoid Arthritis NCT01394276
A Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to DMARDs or Anti-TNF Completed Rheumatoid Arthritis NCT01326962
A Non-Interventional Study in Rheumatoid Arthritis Patients Treated With Tocilizumab (RoActemra/Actemra) Completed Rheumatoid Arthritis NCT01613378
Comparative Study to Evaluate the Pharmacokinetics of BAT1806 vs Actemra® in Healthy Subjects Active, not recruiting Rheumatoid Arthritis NCT03606876
Request for Single Patient IND for Compassionate/Emergency Use of Tocilizumab No longer available Juvenile Idiopathic Arthritis NCT00862758
A Study of Tocilizumab Added to DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to DMARDs. Completed Rheumatoid Arthritis NCT00996203
An Observational Study to Evaluate the Clinical Effectiveness, Quality of Life, Safety and Tolerability of Tocilizumab (TCZ) in Patients With Rheumatoid Arthritis (RA) in Daily Clinical Practice Completed Rheumatoid Arthritis NCT02552940
A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to DMARDs (REMISSION) Completed Rheumatoid Arthritis NCT01610791
A Study of the Effects of RoActemra/Actemra (Tocilizumab) on Neutrophils in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Biologic and/or Non-biologic DMARDs. Completed Rheumatoid Arthritis NCT01195272
TARGET GCAT Registry Recruiting Giant Cell Arteritis NCT04049071
A Pharmacodynamic Study to Evaluate Neutrophil Distribution Kinetics and Function Following Single-Dose RoActemra/Actemra (Tocilizumab) in Healthy Volunteers Completed Healthy Volunteer NCT01991990
Characterization of Non-Steroidal Anti-Inflammatory Drug (NSAID) Intake in Rheumatoid Arthritis (RA) Participants on Tocilizumab (RoACTEMRA®) Treatment Completed Rheumatoid Arthritis NCT03112213
MEthotrexate Versus TOcilizumab for Treatment of GIant Cell Arteritis: a Multicenter, Randomized, Controlled Trial Recruiting Giant Cell Arteritis NCT03892785
A Study of The Effect of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate on Articular Damage in The Hand in Patients With Moderate to Severe Rheumatoid Arthritis Who Have an Inadequate Response to Non-Biological DMARDs Withdrawn Rheumatoid Arthritis NCT01878318
Observational Study of Tocilizumab in Participants With Rheumatoid Arthritis in Australia Completed Rheumatoid Arthritis NCT01683604
Ipilimumab, Nivolumab, Tocilizumab and Radiation in Pretreated Patients With Advanced Pancreatic Cancer Not yet recruiting Pancreatic Cancer NCT04258150
A Study Comparing Infusion Rates of Tocilizumab in Patients With Moderate to Severe Rheumatoid Arthritis Completed Rheumatoid Arthritis NCT00887341
Regulation of the Immune System in Response to the Treatment With Tocilizumab in Rheumatoid Arthritis Patients Completed Rheumatoid Arthritis NCT01633346
A Study to Assess the Effect of Tocilizumab on Signs and Symptoms in Patients With Rheumatoid Arthritis Completed Rheumatoid Arthritis NCT00848120
A Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis Completed Rheumatoid Arthritis NCT01245439
A Study to Provide RoActemra/Actemra (Tocilzumab) to Patients With Multicentric Castleman's Disease Who Demonstrated Benefit From Previous RoActemra/Actemra Treatment Completed Castleman's Disease NCT01183598
A Study of Tocilizumab in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Current Non-Biologic DMARDs Completed Rheumatoid Arthritis NCT00810277
A Study of RoActemra/Actemra (Tocilizumab) Plus DMARDs in Patients With Rheumatoid Arthritis Completed Rheumatoid Arthritis NCT01214733
An Observational Study of RoActemra/Actemra (Tocilizumab) in Monotherapy in Patients With Rheumatoid Arthritis Completed Rheumatoid Arthritis NCT01669902
A Study of Tocilizumab as Monotherapy or in Combination With DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis Completed Rheumatoid Arthritis NCT01089023
A Study Assessing the Safety and Efficacy of Subcutaneous RoActemra/Actemra Alone or in Combination With Non-biologic Antirheumatics in Rhuematoid Arthritis Patients in Latin America With Inadequate Response to Non-biologic Antirheumatic Drugs. Completed Rheumatoid Arthritis NCT02011334
A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Current Non-Biologic and/or Biologic DMARDS Completed Rheumatoid Arthritis NCT01149057
TORPEDO Study: A Study on Rapid Effect of Tocilizumab in Patients With Rheumatoid Arthritis With an Inadequate Response to Disease-Modifying Antirheumatic Drugs (DMARDs) or Anti-TNF Completed Rheumatoid Arthritis NCT00977106
Characterization of the Effect of Tocilizumab in Vivo and in Vitro on T Follicular Helper Cells in Rheumatoid Arthritis Patients and Consequence on B Cells Maturation Completed Arthritis, Rheumatoid|Tocilizumab|T-Lymphocytes, Helper-Inducer NCT02569736
A Non-Interventional Study in Patients With Moderate to Severe Rheumatoid Arthritis Treated With RoActemra/Actemra (Tocilizumab) Completed Rheumatoid Arthritis NCT01663506
An Exploratory Study of Tocilizumab in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Current Non-Biologic DMARDs and/or Anti-TNF Therapy. Completed Rheumatoid Arthritis NCT00750880
A Study of Glucocorticoid Use to Evaluate Systematic Methylprednisolone Reduction in Patients With Rheumatoid Arthritis on Background RoActemra/Actemra (Tocilizumab) (ACT-ALONE) Completed Rheumatoid Arthritis NCT01219933
A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Severe Active Rheumatoid Arthritis, Comparing Tapering Versus Maintaining the Methotrexate Dosage Terminated Rheumatoid Arthritis NCT01661140
A Study to Evaluate the Bioequivalence of Tocilizumab Following Subcutaneous Administration Via an Autoinjector (AI 1000-G2) Versus a Pre-Filled Syringe in Healthy Volunteers Completed Healthy Volunteer NCT02678988
IL-6 Regulation of Substrate Metabolism and Influence of Obesity Recruiting Obesity|Healthy NCT03967691
Efficacy and Safety of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis Completed Rheumatoid Arthritis NCT01211834
A Study of the Impact of Methotrexate (MTX) Discontinuation on the Efficacy of Subcutaneous (SC) Tocilizumab (TCZ) With MTX Completed Rheumatoid Arthritis NCT01855789
Effects of Interleukin-6 Inhibition on Vascular, Endothelial and Left Ventricular Function in Rheumatoid Arthritis Recruiting Rheumatoid Arthritis|Inflammation NCT03288584
A Study of Tocilizumab in Patients With Rheumatoid Arthritis Completed Rheumatoid Arthritis NCT01187563
A Study of Tocilizumab + DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis Completed Rheumatoid Arthritis NCT00951275
A Drug Interaction Study Between Tocilizumab, Methotrexate and Simvastatin on Patients With Rheumatoid Arthritis. Completed Rheumatoid Arthritis NCT00365001
Multicenter, Post-marketing, Non-interventional, Observational Study in RA Patients Treated With RoActemra/Actemra (Tocilizumab) Completed Rheumatoid Arthritis NCT02101307
A Study of Tocilizumab and Methotrexate in Combination or as Monotherapy in Treatment-NaĂŻve Patients With Early Rheumatoid Arthritis Completed Rheumatoid Arthritis NCT01034137
A Study of Tocilizumab in Combination With DMARD Therapy in Patients With Active Rheumatoid Arthritis. Completed Rheumatoid Arthritis NCT00773461
Longitudinal Changes in Donor-Derived Cell-Free DNA With Tocilizumab Treatment for Chronic Antibody-Mediated Rejection Enrolling by invitation Rejection Chronic Renal|Kidney Transplant Rejection NCT03859388
A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Non-biologic DMARDs Completed Rheumatoid Arthritis NCT01353859
A Study of RoActemra/Actemra (Tocilizumab) in Combination With DMARDs Versus Current Best Practice DMARD Therapy in Patients With Rheumatoid Arthritis Terminated Rheumatoid Arthritis NCT01251120
To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN) Completed Rheumatoid Arthritis NCT01768572
A Study to Assess the Effect of Tocilizumab Plus Methotrexate on Safety and Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis Completed Rheumatoid Arthritis NCT00754572
A Non-Interventional Study of RoActemra/Actemra (Tocilizumab) Treatment in Patients With Rheumatoid Arthritis Completed Rheumatoid Arthritis NCT01952509
A Study of Subcutaneous RoActemra/Actemra (Tocilizumab) as Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Patients With Active Rheumatoid Arthritis Completed Rheumatoid Arthritis NCT01995201
A Non-Interventional Study in Patients With Rheumatoid Arthritis Who Are Treated With RoActemra/Actemra (Tocilizumab) Withdrawn Rheumatoid Arthritis NCT01893255
A Non-Interventional Study of RoActemra/Actemra (Tocilizumab) in Monotherapy in Patients With Rheumatoid Arthritis (MONACO) Terminated Rheumatoid Arthritis NCT01643863
An Observational Study in Rheumatoid Arthritis Patients Treated With RoActemra/Actemra (Tocilizumab) Completed Rheumatoid Arthritis NCT01565122
A Study to Assess the Safety and Efficacy of Tocilizumab in Patients With Active Rheumatoid Arthritis Completed Rheumatoid Arthritis NCT00109408
Tocilizumab Effect on microRNA Expression and Adipokine Levels in Rheumatoid Arthritis Patients Completed Rheumatoid Arthritis NCT03149796
Study of Tocilizumab (RoActemre) Administered Subcutaneously in Participants With Rheumatoid Arthritis in Everyday Clinical Practice Active, not recruiting Rheumatoid Arthritis NCT02251860
Lymphocyte and Cytokine Disturbances in Polymyalgia Rheumatica Completed Polymyalgia Rheumatica NCT02888496
A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Disease-Modifying Antirheumatic Drugs (DMARDs) (ALABASTER) Completed Rheumatoid Arthritis NCT01235507
A Study to Assess the Effect of Tocilizumab + DMARD Therapy on Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis Completed Rheumatoid Arthritis NCT00106574
An Observational Study of RoActemra/Actemra (Tocilizumab) in Rheumatoid Arthritis Patients Completed Rheumatoid Arthritis NCT01615419
A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis Completed Rheumatoid Arthritis NCT01332994
The Durability of Early RA Disease Control After Tocilizumab Withdrawal: A Canadian Experience Withdrawn Rheumatoid Arthritis NCT03109470
An Extension Study to WA19977 in Patients With Active Polyarticular-Course Juvenile Idiopathic Arthritis Terminated Juvenile Idiopathic Arthritis NCT01575769
A Study of Tocilizumab Plus Non-biological DMARD in Patients With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Non-biological DMARDs Completed Rheumatoid Arthritis NCT01034397
An Observational Study of the Impact of RoActemra/Actemra on Fatigue in Patients With Rheumatoid Arthritis (PEPS) Completed Rheumatoid Arthritis NCT01185522
A Long-Term Safety Extension Study of WA19926 in Participants With Rheumatoid Arthritis Completed Rheumatoid Arthritis NCT01649804
A Study of Subcutaneously Administered Tocilizumab in Patients With Rheumatoid Arthritis Completed Rheumatoid Arthritis NCT00965653
A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Systemic Juvenile Idiopathic Arthritis (JIA) Completed Juvenile Idiopathic Arthritis NCT00642460
A Retrospective Observational Study on Compliance in Patients With Rheumatoid Arthritis on Treatment With RoActemra/Actemra (Tocilizumab) in Clinical Practice (REMISSION II) Completed Rheumatoid Arthritis NCT01649817
A Study to Assess the Effect of Tocilizumab + Methotrexate on Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis Completed Rheumatoid Arthritis NCT00106548
A Study of RoActemra/Actemra (Tocilizumab) With or Without Methotrexate in Patients With Mild to Moderate Rheumatoid Arthritis With an Inadequate Response to Methotrexate Completed Rheumatoid Arthritis NCT01587989
A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate Versus RoActemra/Actemra Monotherapy in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate Completed Rheumatoid Arthritis NCT01399697
A Study to Assess the Effect of Tocilizumab + Methotrexate on Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis Currently on Methotrexate Therapy Completed Rheumatoid Arthritis NCT00106522
Pharmacokinetics/Pharmacodynamics (PK/PD) Equivalence Study of MSB11456 Completed Healthy NCT03282851
A Prospective, Non-Interventional Study of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Active Rheumatoid Arthritis Completed Rheumatoid Arthritis NCT01770834
An Observational Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis (ACTIVATE) Completed Rheumatoid Arthritis NCT01384461
Mild-Intensity Whole Body Hyperthermia (WBH) for Major Depressive Disorder Not yet recruiting Major Depressive Disorder NCT03787290
An Observational Study of RoActemra/Actemra in Patients With Moderate to Severe Rheumatoid Arthritis Completed Rheumatoid Arthritis NCT01375478
An Global Comparative Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis Completed Rheumatoid Arthritis NCT01543503
A Study of the Efficacy and Safety of Tocilizumab for Confirmed Rheumatoid Arthritis (RA) Participants in Clinical Practice Terminated Rheumatoid Arthritis NCT02616328
An Observational Study on Fatigue in Patients With Rheumatoid Arthritis Treated With RoActemra/Actemra (Tocilizumab) Completed Rheumatoid Arthritis NCT01667458
Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation Recruiting Acute Myeloid Leukemia|Acute Lymphoblastic Leukemia|Acute Leukemia|Myelodysplastic Syndromes|Myelodysplastic-Myeloproliferative Diseases|Myeloproliferative Disorder|Non Hodgkin Lymphoma|Hodgkin Lymphoma|Leukemia NCT03434730
An Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis Terminated Rheumatoid Arthritis NCT01277328
Monitoring Epstein-Barr Virus (EBV) Load in Rheumatoid Arthritis Patients Treated With New Immunosuppressive Drugs Unknown status Rheumatoid Arthritis NCT00947492
An Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to DMARDs Completed Rheumatoid Arthritis NCT01388309
An Observational Study on Long-Term Effectiveness and Safety of RoActemra/Actemra (Tocilizumab) in Daily Practice in Patients With Rheumatoid Arthritis (ICHIBAN) Unknown status Rheumatoid Arthritis NCT01194401
A Non-Interventional Study of RoActemra/Actemra in Patients With Moderate to Severe Rheumatoid Arthritis Completed Rheumatoid Arthritis NCT01672970
ASSessing the Effect of Anti-IL-6 Treatment in Myocardial Infarction: The ASSAIL-MI Trial Active, not recruiting Coronary Disease|Myocardial Infarction NCT03004703
Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA) Completed Rheumatoid Arthritis NCT02097524
A Study of Combination Treatment With MabThera (Rituximab) and RoActemra (Tocilizumab) Versus RoActemra in Patients With Rheumatoid Arthritis With an Incomplete Response to Methotrexate Terminated Rheumatoid Arthritis NCT00845832
Cell Therapy for Immunomodulation in Kidney Transplantation Recruiting Kidney Transplantation NCT03867617
Checkpoint Inhibitor Induced Colitis and Arthritis -Immunomodulation With IL-6 Blockade and Exploration of Disease Mechanisms Recruiting Solid Tumor|Colitis|Arthritis NCT03601611
An Observational Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis Treated With Glucocorticoids Completed Rheumatoid Arthritis NCT01564901
An Observational Study of Glucocorticoid Use in Patients With Rheumatoid Arthritis on Treatment With RoActemra/Actemra (Tocilizumab) Completed Rheumatoid Arthritis NCT01392001
IL-6 Inhibition for Modulating Inflammation After Cardiac Arrest Active, not recruiting Heart Arrest|Out-Of-Hospital Cardiac Arrest|Systemic Inflammatory Response Syndrome NCT03863015
Rheumatoid Arthritis Treatment After First Anti-TNF INvestiGation Recruiting Rheumatoid Arthritis NCT03100253
An Observational Study of RoActemra/Actemra (Tocilizumab) in Smoking Versus Non-Smoking Patients With Rheumatoid Arthritis Completed Rheumatoid Arthritis NCT01337388
ARMONIA: An Observational Study of Biologic Drugs in Monotherapy or Combination With DMARDs in Italian Clinical Practice and the Efficacy and Safety of RoActemra/Actemra (Tocilizumab) Monotherapy in Patients With Rheumatoid Arthritis Completed Rheumatoid Arthritis NCT01791205
A Comparative Study to Observe the Effect of Concomitant Use of Corticosteroid Treatment in Rheumatoid Arthritis (RA) Participants Who Are Treated With a Tumor Necrosis Factor (TNF) Inhibitor or Tocilizumab (TCZ) as Their Second Biological Treatment. Completed Rheumatoid Arthritis NCT02679001
Ectopic Adipose Tissue, Exercise Training and IL-6 Unknown status Adiposity NCT02901496
Evaluation of the BRADA and ABILHAND Questionnaires Completed Rheumatoid Arthritis NCT00938444
Anti-il6 Treatment of Serious COVID-19 Disease With Threatening Respiratory Failure Not yet recruiting Corona Virus Disease NCT04322773
Evaluation of Desensitization Protocols in HLA-incompatible Kidney-transplant Candidates Recruiting End-stage Renal Disease|Kidney Transplantation|Hla-incompatible Kidney Transplant Candidates NCT03507348
AIDS 347: IL-6 Blockade in Treated HIV Infection Active, not recruiting HIV Infections NCT02049437
Rotation or Change of Biotherapy After First Anti-TNF Treatment Failure for Rheumatoid Arthritis Unknown status Rheumatoid Arthritis NCT01000441
A Retrospective, Observational Study of RoActemra/Actemra (Tocilizumab) in Clinical Practice in Patients With Rheumatoid Arthritis Completed Rheumatoid Arthritis NCT01921478
U-Act-After: An Observational Study on Long-Term Efficacy of Tight Control RoActemra/Actemra (Tocilizumab) and/or Methotrexate in Patients With Early Rheumatoid Arthritis Who Have Participated in the U-Act-Early Study (ML22497) Completed Rheumatoid Arthritis NCT01918267
An Observational Study on Long-Term Efficacy and Safety of RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis (FAct) Completed Rheumatoid Arthritis NCT01483326
Study of MRA for Polyarticular Juvenile Idiopathic Arthritis (pJIA) Completed Systemic Juvenile Idiopathic Arthritis NCT00144664
An Observational Study of Dosage Patterns in Routine Clinical Practice in Patients With Rheumatoid Arthritis (ACT-LIFE) Completed Rheumatoid Arthritis NCT01338545
A Dose Escalation Study of RO7082859 as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma Recruiting Non-Hodgkin's Lymphoma NCT03075696
Anti-Biopharmaceutical Immunization: Prediction and Analysis of Clinical Relevance to Minimize the Risk of Immunization in Rheumatoid Arthritis Patients or Juvenile Idiopathic Arthritis Patients Unknown status Rheumatoid Arthritis|Juvenile Idiopathic Arthritis NCT02116504
Treg Modulation With CD28 and IL-6 Receptor Antagonists Recruiting Living-Donor Kidney Transplant|Kidney Transplant Recipients NCT04066114
Korean College of Rheumatology Biologics Registry Recruiting Rheumatoid Arthritis|Ankylosing Spondylitis|Psoriatic Arthritis NCT01965132
A Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Therapy in Participants With Previously Untreated Diffuse Large B-Cell Lymphoma Who Are Unable to Tolerate Full-Dose Chemotherapy Recruiting Diffuse Large B-cell Lymphoma NCT03677154
An Open-Label Phase lB Study of RO7082859 and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma Recruiting Non-Hodgkins Lymphoma NCT03533283
Role of Interleukin-6 in Exercise Completed Diabetes Mellitus, Type 2|Obesity NCT01073826
Allogeneic Stem Cell Transplantation for Patients With Multiple Myeloma Withdrawn Multiple Myeloma|Myeloma-Multiple NCT02447055
Treatment Tapering in JIA With Inactive Disease Active, not recruiting Juvenile Idiopathic Arthritis NCT02840175
Comparative Study of BAT1806 to RoActemra® in Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate Recruiting Rheumatoid Arthritis NCT03830203
Dose Reduction for Early Rheumatoid Arthritis Patients With Low Disease Activity Recruiting Rheumatoid Arthritis NCT02466581
A Phase IIb Study for ALX-0061 Monotherapy in Subjects With Rheumatoid Arthritis Completed Rheumatoid Arthritis NCT02287922
Impact of Acute and Chronic Inflammation on Cytochromes P450 Activity Measured With Dried Blood Spot Unknown status Inflammation NCT03262051
Phaseâ…˘Open-label Study of MRA for Rheumatoid Arthritis(RA) Completed Rheumatoid Arthritis NCT00380601
Study of MRA in Patients With Rheumatoid Arthritis (RA) Completed Rheumatoid Arthritis NCT00144651
Long-term Treatment Study of MRA for Polyarticular Juvenile Idiopathic Arthritis (pJIA) Completed Polyarticular Juvenile Idiopathic Arthritis NCT00144625
Long-term Treatment Study of MRA for Systemic Juvenile Idiopathic Arthritis (sJIA) Completed Systemic Juvenile Idiopathic Arthritis NCT00144612
Long-term Treatment Study of MRA for Rheumatoid Arthritis (RA) From Study MRA220JP or MRA221JP Completed Rheumatoid Arthritis NCT00144586
Clinical Pharmacology Study of MRA in Patient With Rheumatoid Arthritis (RA) With Renal Impairment Completed Rheumatoid Arthritis NCT00144573
Drug-Drug Interaction Study of MRA in Patient With Rheumatoid Arthritis (RA) Completed Rheumatoid Arthritis NCT00144560
Long-term Treatment Study of MRA for Rheumatoid Arthritis (RA) From Study MRA012JP Completed Rheumatoid Arthritis NCT00144547
Long-term Treatment Study of MRA for Rheumatoid Arthritis (RA) From Study MRA213JP Completed Rheumatoid Arthritis NCT00144534
A Study of Duration of Maintained Efficacy in Rheumatoid Arthritis (RA) Patients Off Treatment With MRA(a Development Code of Tocilizumab, an Anti IL-6 Receptor Monoclonal Antibody.) Completed Rheumatoid Arthritis NCT00661284
Development and Analysis of a Stool Bank for Cancer Patients Recruiting Carcinoma, Non-Small-Cell Lung|Carcinoma, Colorectal NCT04291755
Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Terminated Leukemia, Myeloid, Acute NCT02057770
Usefulness of Non TNF Usage in RA Patients Recruiting Rheumatoid Arthritis NCT03784261
A Randomized, Multi-Center Biomarker Trial to Predict Therapeutic Responses of Patients With Rheumatoid Arthritis to a Specific Biologic Mode of Action Completed Rheumatoid Arthritis NCT01638715
The Registry Study of Takayasu Arteritis in East China Recruiting Takayasu Arteritis|Mechanisms, Defense|Pregnancy Related|Treatment Refusal|Outcome NCT03893136
Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia Recruiting CD19 Positive|CD20 Positive|Recurrent Chronic Lymphocytic Leukemia|Recurrent Diffuse Large B-Cell Lymphoma|Recurrent Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Diffuse Large B-Cell Lymphoma|Refractory Follicular Lymphoma|Refractory Mantle Cell Lymphoma|Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma|Refractory Small Lymphocytic Lymphoma NCT04007029
A Study of RO7172508 in Patients With Locally Advanced and/or Metastatic CEA-Positive Solid Tumors Completed Solid Tumors NCT03539484
Clinical Trial Evaluating Methotrexate + Biologic Versus Methotrexate, Salazopyrine and Hydroxychloroquine in Patients With Rheumatoid Arthritis and Insufficient Response to Methotrexate Unknown status Rheumatoid Arthritis|Insufficient Response to Methotrexate. NCT02714634
A Study of RO6958688 in Participants With Locally Advanced and/or Metastatic Carcinoembryonic Antigen Positive Solid Tumors Completed Solid Tumors NCT02324257
Active Conventional Therapy Compared to Three Different Biologic Treatments in Early Rheumatoid Arthritis With Subsequent Dose Reduction Active, not recruiting Rheumatoid Arthritis NCT01491815
A Study Comparing Biologics + Methotrexate With Biologics + Tacrolimus in Patients With Rheumatoid Arthritis (RA) Recruiting Rheumatoid Arthritis (RA) NCT03737708
CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL Recruiting B-cell Acute Lymphoblastic Leukemia|Acute Lymphocytic Leukemia, Pediatric NCT03467256
Evaluation Effects of Treatment With IL-6R Inhibitor on Clinical Response and Biomarkers in Patients With Rheumatoid Arthritis (RA) Not Responding to DMARDs and/or a First Biological Agent. Unknown status Rheumatoid Arthritis (RA) NCT01835613
Personalized Targeted Preparative Regimen Before T-depleted Allogeneic HSCT in Children With Chemoresistent Acute Leukemias Not yet recruiting Refractory Acute Myeloid Leukemia|Refractory Acute Lymphoblastic Leukemia NCT04000698
Study of MRA for Systemic Juvenile Idiopathic Arthritis (sJIA) Completed Systemic Juvenile Idiopathic Arthritis NCT00144599
Phase III Comparative Study(Open-Label) of MRA for Rheumatoid Arthritis(RA) Completed Rheumatoid Arthritis NCT00144508
the Bispecific PSMAxCD3 Antibody CC-1 in Patients With Castration Resistant Prostate Carcinoma Recruiting Castration-Resistant Prostatic Cancer NCT04104607
A Phase Ib Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Cibisatamab in Combination With Atezolizumab After Pretreatment With Obinutuzumab in Participants With Previously Treated Metastatic Colorectal Adenocarcinoma Active, not recruiting Colorectal Cancer NCT03866239
Metoprolol for the Treatment of Cytokine Release Syndrome in Patients Treated With Chimeric Antigen Receptor T Cells Recruiting Solid Tumor|Hematologial Malignancy NCT04082910
A Study of RO7082859 in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Non-Hodgkin Lymphomas and Participants With DLBCL Recruiting B-Cell Lymphoma|Non-Hodgkin Lymphoma NCT03467373
Ustekinumab for the Treatment of Relapse of Refractory Giant Cell Arteritis Recruiting Patients Relapsing Refractory Giant Cell Arteritis NCT03711448
A Retrospective Observational Study on the Use of Biologics in Monotherapy in Patients With Rheumatoid Arthritis Completed Rheumatoid Arthritis NCT01834807
Efficacy and Safety of CDP6038 in Patients With Rheumatoid Arthritis With an Unsuccessful Response to Anti-Tumor Necrosis Factor (Anti-TNF) Therapy Completed Rheumatoid Arthritis NCT01242488
A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-based Treatment Combinations in Patients With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy Recruiting Urothelial Carcinoma NCT03869190
Clinical and Immunogenetic Characterization of Giant Cell Arteritis (GCA) and Polymyalgia Rheumatica (PMR) Recruiting Giant Cell Arteritis|Polymyalgia Rheumatica NCT04102930
Biomarkers in Rheumatoid Arthritis Treated With Anti-interleukin-6 Therapy Recruiting Rheumatoid Arthritis NCT04281602
Impact of the Persistence of Inflammation at Doppler Ultrasound Level on the Structural Evolution of Erosion in Rheumatoid Arthritis Treated With Biotherapy Completed Rheumatoid Arthritis NCT02531061
Study of Refractory and/or Relapsing TAkayasu aRTeritis Recruiting Systemic Vasculitis|Arteritis, Takayasu|Arteritis NCT03543527
Abatacept in earLy Onset Polymyalgia Rheumatica: Study ALORS Recruiting Polymyalgia Rheumatica NCT03632187
Ultrasound and Withdrawal of Biological DMARDs in Rheumatoid Arthritis Recruiting Rheumatoid Arthritis NCT01602302
Using Adalimumab Serum Concentration to Choose a Subsequent Biological DMARD in Rheumatoid Arthritis Patients Failing Adalimumab Treatment Recruiting Rheumatoid Arthritis NCT04251741
Depression and Anxiety in Rheumatoid Arthritis Completed Rheumatoid Arthritis|Depression|Anxiety NCT02122406
Cardiovascular Risk and Chronic Inflammatory Rheumatism Recruiting Rheumatology|Cardiovascular Diseases|Arthritis, Rheumatoid|Spondyloarthritis NCT03187444
Effects of Antirheumatic Treatment on Levels of Survivin in Rheumatoid Arthritis Patients Recruiting Rheumatoid Arthritis NCT03440892
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide, RO7082859 + Lenalidomide, and RO7082859 + Lenalidomide + Obinutuzumab in Participants With Relapsed or Refractory Follicular Lymphoma Not yet recruiting Follicular Lymphoma NCT04246086
A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma Recruiting B-cell Non-Hodgkin Lymphoma NCT03671018
Comparative Study (Double-Blind) of MRA for Rheumatoid Arthritis (RA) Completed Rheumatoid Arthritis NCT00144521
RETRO (REduction of Therapy in RA Patients in Ongoing Remission) Unknown status Rheumatoid Arthritis NCT02779114
An Observational Study in Clinical Practice Management of Patients With Biological Drugs in Monotherapy Completed Rheumatoid Arthritis NCT01664117
A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma Recruiting B-cell Non-Hodgkin Lymphoma NCT03677141
A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) Recruiting Carcinoma, Non-Small-Cell Lung NCT03337698
Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma Recruiting Lymphoma|Lymphoma, B-Cell|Immune System Diseases|Immunoproliferative Disorders|Lymphatic Diseases NCT03696784
Predicting Hospitalized Infection in Patients With Chronic Inflammatory Arthritis Treated With Biological Drugs Completed Rheumatoid Arthritis|Spondyloarthritis|Psoriatic Arthritis NCT03496831
Study of Tisagenlecleucel in Chinese Pediatric and Young Adult Subjects With Relapsed or Refractory B-cell ALL Not yet recruiting B-cell Acute Lymphoblastic Leukemia NCT04156659
An Open-label Extension Study of Canakinumab in Patients With Systemic Juvenile Idiopathic Arthritis and Active Systemic Manifestations Manifestations and Response Characterization Study in Canakinumab Treatment-naĂŻve Patients With Active SJIA With and Without Fever. Completed Systemic Juvenile Idiopathic Arthritis NCT00891046
A Retrospective Chart Review on the Use of Biologics in Monotherapy for the Treatment of Patients With Rheumatoid Arthritis Completed Rheumatoid Arthritis NCT01640548
An Observational Study to Describe in Routine Clinical Practice the Treatment Patterns of Usage of Biological DMARDs in RA Patients. Completed Rheumatoid Arthritis NCT02590562
Comparative Analysis of Outcomes Among Patients Initiating Xeljanz in Combination With Oral MTX Who Withdraw MTX Versus Continue MTX Completed Rheumatoid Arthritis NCT03975790
Pragmatic Clinical Trials in Scleroderma Not yet recruiting Scleroderma, Systemic|Sclerosis, Systemic NCT03610217
Enhancing Patient Ability to Understand and Utilize Complex Information Concerning Medication Self-management Completed Rheumatoid Arthritis NCT02820038

References

Publication DOI Pubmed PMCID
Anti-tumor effect of inhibition of IL-6 signaling in mucoepidermoid carcinoma. Oncotarget Daiki Mochizuki, April Adams, Kristy A Warner, Zhaocheng Zhang, Alexander T Pearson, Kiyoshi Misawa, Scott A McLean, Gregory T Wolf, Jacques E Nör, 6, 26, 2015-09-08, None, 10.18632/oncotarget.4477 10.18632/oncotarget.4477 26287605 PMC4673202

Filter data

Compound Tocilizumab
Experiment types Flow cytometry , Microvessel density staining, Mouse weight, SRB assay , Salisphere assay, Survival Rate, Tumor volume, Western Blot
Concentrations 0.00, 0.01, 0.10, 1.00, 10.00, 5.00
Cell lines HDMEC, UM-HMC-1, UM-HMC-3A, UM-HMC-3B, UM-HMC-3B (xenograft)
Organisms Homo sapiens, Mus musculus
Animal models C.B-17 scid
STAT proteins STAT3, p-STAT3
Other AKT, ERK, GAPDH, VEGF, p-AKT, p-ERK

Experiments

Compound Experiment type Investigated event Concentration Cell line Organism Animal model Stat protein Details
Tocilizumab Tumor volume Influence on tumor growth 5.00 mg/kg UM-HMC-3B (xenograft) Mus musculus C.B-17 scid p-STAT3
Tocilizumab Mouse weight Influence on tumor growth 5.00 mg/kg UM-HMC-3B (xenograft) Mus musculus C.B-17 scid STAT3
Tocilizumab Survival Rate Influence on tumor growth 5.00 mg/kg UM-HMC-3B (xenograft) Mus musculus C.B-17 scid
Tocilizumab Western Blot Influence on protein activity in tumor tissue 5.00 mg/kg UM-HMC-3B (xenograft) Mus musculus C.B-17 scid
Tocilizumab Western Blot Influence on protein activity in tumor tissue 5.00 mg/kg UM-HMC-3B (xenograft) Mus musculus C.B-17 scid
Tocilizumab Western Blot Influence on protein activity in tumor tissue 5.00 mg/kg UM-HMC-3B (xenograft) Mus musculus C.B-17 scid
Tocilizumab Western Blot Influence on protein activity in tumor tissue 5.00 mg/kg UM-HMC-3B (xenograft) Mus musculus C.B-17 scid
Tocilizumab SRB assay Influence on cell viability 0.01 µM UM-HMC-1 Homo sapiens
Tocilizumab SRB assay Influence on cell viability 0.01 µM UM-HMC-3A Homo sapiens
Tocilizumab SRB assay Influence on cell viability 0.01 µM UM-HMC-3B Homo sapiens
Tocilizumab SRB assay Influence on cell viability 0.01 µM HDMEC Homo sapiens
Tocilizumab SRB assay Influence on cell viability 0.10 µM UM-HMC-1 Homo sapiens
Tocilizumab SRB assay Influence on cell viability 0.10 µM UM-HMC-3A Homo sapiens
Tocilizumab SRB assay Influence on cell viability 0.10 µM UM-HMC-3B Homo sapiens
Tocilizumab SRB assay Influence on cell viability 0.10 µM HDMEC Homo sapiens
Tocilizumab SRB assay Influence on cell viability 1.00 µM UM-HMC-1 Homo sapiens
Tocilizumab SRB assay Influence on cell viability 1.00 µM UM-HMC-3A Homo sapiens
Tocilizumab SRB assay Influence on cell viability 1.00 µM UM-HMC-3B Homo sapiens
Tocilizumab SRB assay Influence on cell viability 1.00 µM HDMEC Homo sapiens
Tocilizumab SRB assay Influence on cell viability 10.00 µM UM-HMC-1 Homo sapiens
Tocilizumab SRB assay Influence on cell viability 10.00 µM UM-HMC-3A Homo sapiens
Tocilizumab SRB assay Influence on cell viability 10.00 µM UM-HMC-3B Homo sapiens
Tocilizumab SRB assay Influence on cell viability 10.00 µM HDMEC Homo sapiens
Tocilizumab Flow cytometry Influence on cell cycle 1.00 µM UM-HMC-3B Homo sapiens
Tocilizumab Flow cytometry Influence on cell cycle 10.00 µM UM-HMC-3B Homo sapiens
Tocilizumab Microvessel density staining Influence on tumor growth 5.00 mg/kg UM-HMC-3B (xenograft) Mus musculus C.B-17 scid
Tocilizumab Western Blot Influence on protein activity in tumor tissue 5.00 mg/kg UM-HMC-3B (xenograft) Mus musculus C.B-17 scid
Tocilizumab Western Blot Influence on protein activity 0.00 µM UM-HMC-1 Homo sapiens p-STAT3
Tocilizumab Western Blot Influence on protein activity 0.01 µM UM-HMC-1 Homo sapiens p-STAT3
Tocilizumab Western Blot Influence on protein activity 0.10 µM UM-HMC-1 Homo sapiens p-STAT3
Tocilizumab Western Blot Influence on protein activity 0.00 µM UM-HMC-1 Homo sapiens STAT3
Tocilizumab Western Blot Influence on protein activity 0.01 µM UM-HMC-1 Homo sapiens STAT3
Tocilizumab Western Blot Influence on protein activity 0.10 µM UM-HMC-1 Homo sapiens STAT3
Tocilizumab Western Blot Influence on protein activity 0.00 µM UM-HMC-1 Homo sapiens
Tocilizumab Western Blot Influence on protein activity 0.01 µM UM-HMC-1 Homo sapiens
Tocilizumab Western Blot Influence on protein activity 0.10 µM UM-HMC-1 Homo sapiens
Tocilizumab Western Blot Influence on protein activity 0.00 µM UM-HMC-1 Homo sapiens
Tocilizumab Western Blot Influence on protein activity 0.01 µM UM-HMC-1 Homo sapiens
Tocilizumab Western Blot Influence on protein activity 0.10 µM UM-HMC-1 Homo sapiens
Tocilizumab Western Blot Influence on protein activity 0.00 µM UM-HMC-1 Homo sapiens
Tocilizumab Western Blot Influence on protein activity 0.01 µM UM-HMC-1 Homo sapiens
Tocilizumab Western Blot Influence on protein activity 0.10 µM UM-HMC-1 Homo sapiens
Tocilizumab Western Blot Influence on protein activity 0.00 µM UM-HMC-1 Homo sapiens
Tocilizumab Western Blot Influence on protein activity 0.01 µM UM-HMC-1 Homo sapiens
Tocilizumab Western Blot Influence on protein activity 0.10 µM UM-HMC-1 Homo sapiens
Tocilizumab Western Blot Influence on protein activity 0.00 µM UM-HMC-1 Homo sapiens
Tocilizumab Western Blot Influence on protein activity 0.01 µM UM-HMC-1 Homo sapiens
Tocilizumab Western Blot Influence on protein activity 0.10 µM UM-HMC-1 Homo sapiens
Tocilizumab Western Blot Influence on protein activity in presence of rhIL-6 0.00 µM UM-HMC-3B Homo sapiens p-STAT3
Tocilizumab Western Blot Influence on protein activity in presence of rhIL-6 0.01 µM UM-HMC-3B Homo sapiens p-STAT3
Tocilizumab Western Blot Influence on protein activity in presence of rhIL-6 0.10 µM UM-HMC-3B Homo sapiens p-STAT3
Tocilizumab Western Blot Influence on protein activity in presence of rhIL-6 0.00 µM UM-HMC-3B Homo sapiens STAT3
Tocilizumab Western Blot Influence on protein activity in presence of rhIL-6 0.01 µM UM-HMC-3B Homo sapiens STAT3
Tocilizumab Western Blot Influence on protein activity in presence of rhIL-6 0.10 µM UM-HMC-3B Homo sapiens STAT3
Tocilizumab Western Blot Influence on protein activity in presence of rhIL-6 0.00 µM UM-HMC-3B Homo sapiens
Tocilizumab Western Blot Influence on protein activity in presence of rhIL-6 0.01 µM UM-HMC-3B Homo sapiens
Tocilizumab Western Blot Influence on protein activity in presence of rhIL-6 0.10 µM UM-HMC-3B Homo sapiens
Tocilizumab Western Blot Influence on protein activity in presence of rhIL-6 0.00 µM UM-HMC-3B Homo sapiens
Tocilizumab Western Blot Influence on protein activity in presence of rhIL-6 0.01 µM UM-HMC-3B Homo sapiens
Tocilizumab Western Blot Influence on protein activity in presence of rhIL-6 0.10 µM UM-HMC-3B Homo sapiens
Tocilizumab Western Blot Influence on protein activity in presence of rhIL-6 0.00 µM UM-HMC-3B Homo sapiens
Tocilizumab Western Blot Influence on protein activity in presence of rhIL-6 0.01 µM UM-HMC-3B Homo sapiens
Tocilizumab Western Blot Influence on protein activity in presence of rhIL-6 0.10 µM UM-HMC-3B Homo sapiens
Tocilizumab Western Blot Influence on protein activity in presence of rhIL-6 0.00 µM UM-HMC-3B Homo sapiens
Tocilizumab Western Blot Influence on protein activity in presence of rhIL-6 0.01 µM UM-HMC-3B Homo sapiens
Tocilizumab Western Blot Influence on protein activity in presence of rhIL-6 0.10 µM UM-HMC-3B Homo sapiens
Tocilizumab Western Blot Influence on protein activity in presence of rhIL-6 0.00 µM UM-HMC-3B Homo sapiens
Tocilizumab Western Blot Influence on protein activity in presence of rhIL-6 0.01 µM UM-HMC-3B Homo sapiens
Tocilizumab Western Blot Influence on protein activity in presence of rhIL-6 0.10 µM UM-HMC-3B Homo sapiens
Tocilizumab Western Blot Influence on protein activity in presence of conditionend medium 0.00 µM UM-HMC-3B Homo sapiens p-STAT3
Tocilizumab Western Blot Influence on protein activity in presence of conditionend medium 0.01 µM UM-HMC-3B Homo sapiens p-STAT3
Tocilizumab Western Blot Influence on protein activity in presence of conditionend medium 0.10 µM UM-HMC-3B Homo sapiens p-STAT3
Tocilizumab Western Blot Influence on protein activity in presence of conditionend medium 0.00 µM UM-HMC-3B Homo sapiens STAT3
Tocilizumab Western Blot Influence on protein activity in presence of conditionend medium 0.01 µM UM-HMC-3B Homo sapiens STAT3
Tocilizumab Western Blot Influence on protein activity in presence of conditionend medium 0.10 µM UM-HMC-3B Homo sapiens STAT3
Tocilizumab Western Blot Influence on protein activity in presence of conditionend medium 0.00 µM UM-HMC-3B Homo sapiens
Tocilizumab Western Blot Influence on protein activity in presence of conditionend medium 0.01 µM UM-HMC-3B Homo sapiens
Tocilizumab Western Blot Influence on protein activity in presence of conditionend medium 0.10 µM UM-HMC-3B Homo sapiens
Tocilizumab Western Blot Influence on protein activity in presence of conditionend medium 0.00 µM UM-HMC-3B Homo sapiens
Tocilizumab Western Blot Influence on protein activity in presence of conditionend medium 0.01 µM UM-HMC-3B Homo sapiens
Tocilizumab Western Blot Influence on protein activity in presence of conditionend medium 0.10 µM UM-HMC-3B Homo sapiens
Tocilizumab Western Blot Influence on protein activity in presence of conditionend medium 0.00 µM UM-HMC-3B Homo sapiens
Tocilizumab Western Blot Influence on protein activity in presence of conditionend medium 0.01 µM UM-HMC-3B Homo sapiens
Tocilizumab Western Blot Influence on protein activity in presence of conditionend medium 0.10 µM UM-HMC-3B Homo sapiens
Tocilizumab Western Blot Influence on protein activity in presence of conditionend medium 0.00 µM UM-HMC-3B Homo sapiens
Tocilizumab Western Blot Influence on protein activity in presence of conditionend medium 0.01 µM UM-HMC-3B Homo sapiens
Tocilizumab Western Blot Influence on protein activity in presence of conditionend medium 0.10 µM UM-HMC-3B Homo sapiens
Tocilizumab Western Blot Influence on protein activity in presence of conditionend medium 0.00 µM UM-HMC-3B Homo sapiens
Tocilizumab Western Blot Influence on protein activity in presence of conditionend medium 0.01 µM UM-HMC-3B Homo sapiens
Tocilizumab Western Blot Influence on protein activity in presence of conditionend medium 0.10 µM UM-HMC-3B Homo sapiens
Tocilizumab Salisphere assay Influence on cancer stem cells 0.01 µM UM-HMC-3B Homo sapiens
Tocilizumab Salisphere assay Influence on cancer stem cells 0.10 µM UM-HMC-3B Homo sapiens
Tocilizumab Salisphere assay Influence on cancer stem cells 1.00 µM UM-HMC-3B Homo sapiens